Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

De novo design of miniproteins targeting GPCRs.

Nature·2026
Same author

<i>In vivo</i> HSC gene therapy enables sustained eCD4-Ig expression for SIV prevention.

Molecular therapy. Advances·2026
Same author

In vitro and in vivo base editing of CCR5 in hematopoietic stem cells confers HIV-1 resistance.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same author

Junction opener enables CAR T cell treatment of solid tumors.

Scientific reports·2026
Same author

DSG2-Directed CAR-T Cells Safely and Universally Eliminate Solid Tumors.

Research square·2026
Same author

Oncolytic adenoviruses in bladder and kidney cancers: emerging strategies and next frontiers.

Frontiers in microbiology·2025

Related Experiment Video

Updated: Jul 8, 2026

High-Efficiency Transduction of Liver Cancer Cells by Recombinant Adeno-Associated Virus Serotype 3 Vectors
19:02

High-Efficiency Transduction of Liver Cancer Cells by Recombinant Adeno-Associated Virus Serotype 3 Vectors

Published on: March 22, 2011

Targeting of adenovirus vectors to tumor cells does not enable efficient transduction of breast cancer metastases.

Dmitry M Shayakhmetov1, Zong-Yi Li, Shaoheng Ni

  • 1Division of Medical Genetics, University of Washington, Seattle, Washington 98195, USA.

Cancer Research
|February 28, 2002
PubMed
Summary

Capsid-modified oncolytic adenoviruses show promise for targeting tumors. However, systemic delivery to liver metastases requires improved accessibility strategies beyond tropism alone.

More Related Videos

Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer
07:13

Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer

Published on: March 26, 2014

Modeling Breast Cancer via an Intraductal Injection of Cre-expressing Adenovirus into the Mouse Mammary Gland
06:29

Modeling Breast Cancer via an Intraductal Injection of Cre-expressing Adenovirus into the Mouse Mammary Gland

Published on: June 7, 2019

Related Experiment Videos

Last Updated: Jul 8, 2026

High-Efficiency Transduction of Liver Cancer Cells by Recombinant Adeno-Associated Virus Serotype 3 Vectors
19:02

High-Efficiency Transduction of Liver Cancer Cells by Recombinant Adeno-Associated Virus Serotype 3 Vectors

Published on: March 22, 2011

Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer
07:13

Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer

Published on: March 26, 2014

Modeling Breast Cancer via an Intraductal Injection of Cre-expressing Adenovirus into the Mouse Mammary Gland
06:29

Modeling Breast Cancer via an Intraductal Injection of Cre-expressing Adenovirus into the Mouse Mammary Gland

Published on: June 7, 2019

Area of Science:

  • Oncolytic virotherapy
  • Gene therapy
  • Cancer research

Background:

  • Targeting oncolytic adenoviruses to tumors can improve efficacy and safety.
  • A novel Ad5/35 vector with Ad35 fiber components was developed for coxsackievirus adenovirus receptor-independent infection.

Purpose of the Study:

  • To evaluate the tumor-specific infection potential of the Ad5/35 vector.
  • To assess the vector's efficacy in targeting liver metastases in a preclinical model.

Main Methods:

  • In vitro transduction of human breast cancer cells and mouse hepatocytes.
  • Systemic administration of Ad5 and Ad5/35 vectors in a mouse model of breast cancer liver metastasis.
  • Analysis of vector transduction in tumor metastases and normal liver tissue.

Main Results:

  • Ad5/35 efficiently transduced breast cancer cells resistant to Ad5 vectors.
  • Primary mouse hepatocytes showed relative refractoriness to Ad5/35.
  • Ad5/35 transduced only 8% of liver metastases, with susceptibility linked to tumor vascularization and accessibility.
  • Standard Ad5 vector transduced hepatocytes but not metastases.

Conclusions:

  • The Ad5/35 vector demonstrates tumor-specific tropism but limited transduction of liver metastases.
  • Accessibility of tumor cells, influenced by tumor microenvironment and vascularization, is crucial for systemic oncolytic adenovirus delivery.
  • Novel strategies are needed to enhance tumor cell accessibility for effective oncolytic virotherapy.